Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Athersys. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Athersys's earnings available for a low price, and how does
this compare to other companies in the same industry?
Athersys's earnings are expected to grow significantly at over 20% yearly.
Athersys's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Athersys's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Gil Van Bokkelen, Ph.D. serves as an Investment Advisor to Early Stage Partners, a venture capital fund based in Ohio. Dr. Van Bokkelen co-founded Athersys, Inc. in October 1995 and has been its Chief Executive Officer since 1995. He served as the President at Athersys, Inc. until May 2006. Dr. Van Bokkelen also played a fundamental role in developing the SMC technology. He has been the Chairman at Athersys, Inc. since August 2000 and has been its Director since 1995. He has been a Director and a Member of Health Section Governing Board at Biotechnology Industry Organization since July 2011. He has been Director of Alliance for Regenerative Medicine since 2018. He serves on the board of the Alliance for Regenerative Medicine and served as chairman from 2010 through 2012, a Washington D.C. based consortium of companies, patient advocacy groups, disease foundations, and clinical and research institutions that are committed to the advancement of the field of regenerative medicine, and served ex officio from 2013 to 2014. He served as a Member of the Biotechnology Industry Organization (BIO) Emerging Companies Section Board from 2001 to 2004. Dr. Van Bokkelen served as a Member of the Kent State University Board of Trustees from 2001 to 2004. He is the recipient of numerous awards, including the Ernst & Young Entrepreneur of the Year award and SBN Visionary in Business Award. Dr. Van Bokkelen is also the Chairman of the Board of Governors for the National Center for Regenerative Medicine. He is a co-developer of the Synthetic Human Chromosome technology and has been awarded several patents. Dr. Van Bokkelen holds a Ph.D. in Genetics from Stanford University, a BA in Economics from the University of California at Berkeley and a B.A. in Molecular Biology from the University of California at Berkeley.
Gil's compensation has been consistent with company performance over the past year.
Gil's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Athersys management team is about average.
Gil Van Bokkelen
Senior Vice President of Finance
Senior VP & Head of Global Regulatory Affairs
VP of Regenerative Medicine & Head of Neuroscience Programs
VP of Regenerative Medicine & Head of Cardiopulmonary Programs
Head of Information Technology & Communications and VP
Senior VP of Commercial Manufacturing
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The average tenure for the Athersys board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company’s lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.